{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:57Z","timestamp":1787755797214,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd010615","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000}}],"reference-count":65,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010615.pub2","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:43:07Z","timestamp":1445474587000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma"],"prefix":"10.1002","volume":"2015","author":[{"given":"Tim","family":"Hartmann","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"H\u00fcbel","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"key":"10.1002\/14651858.CD010615.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood.V114.22.3224.3224","article-title":"Mobilization with plerixafor (Mozobil (R)) plus G-CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G-CSF: Results from two randomized placebo-controlled trials in patients with multiple myeloma or non-Hodgkin's lymphoma","volume":"114","author":"Bolwell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD010615.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V110.11.601.601","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor) + G-CSF vs. G-CSF+ placebo for mobilization in non Hodgkin lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation","volume":"110","author":"DiPersio","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.V112.11.1136.1136","article-title":"Months report from the phase 3 study of plerixafor + G-CSF vs. placebo + G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL","volume":"112","author":"DiPersio","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V114.22.2319.2319","article-title":"Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G-CSF versus placebo plus G-CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front-line or rescue mobilization","volume":"114","author":"Micallef","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood.V114.22.3224.3224","article-title":"Mobilization with plerixafor (Mozobil (R)) plus G-CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G-CSF: Results from two randomized placebo-controlled trials in patients with multiple myeloma or non-Hodgkin's lymphoma","volume":"114","author":"Bolwell","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood.V112.11.3312.3312","article-title":"12 months report from a phase 3 study of plerixafor + G-CSF vs. placebo + G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma","volume":"112","author":"DiPersio","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD010615.pub2-BIB0009|cit9","first-page":"137a","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor) + G-CSF vs. G-CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [Abstract No. 445]","volume":"110","author":"DiPersio","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V114.22.2319.2319","article-title":"Similar 1 year survival of patients receiving plerixafor (Mozobil*(R)) plus G-CSF versus placebo plus G-CSF mobilized autologous grafts: Results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front-line or rescue mobilization","volume":"114","author":"Micallef","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","article-title":"Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial","volume":"18","author":"Nademanee","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V114.22.3230.3230","article-title":"Plerixafor (Mozobi (R)) plus G-CSF is more effective than placebo plus G-CSF in mobilizing CD34+ hematopoietic stem cells in patients with multiple myeloma who have low (<20 cells\/{micro}l) peripheral blood CD34+ cell count","volume":"114","author":"Nademanee","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0013|cit13","unstructured":"NCT00665314. Evaluation of the safety and efficacy of the addition of AMD3100 to a G-CSF mobilization regimen in patients with lymphoma (NHL and HD) and multiple myeloma (MM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00665314"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0014|cit14","unstructured":"NCT01301963. Filgrastim with or without plerixafor in treating patients with multiple myeloma previously treated with lenalidomide https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01301963"},{"issue":"5","key":"10.1002\/14651858.CD010615.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"Flomenberg","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood.V114.22.33.33","article-title":"Plerixafor plus G-CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells\/{micro}l < 10","volume":"114","author":"Maziarz","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbmt.2013.01.005","article-title":"Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells","volume":"19","author":"Maziarz","year":"2013","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD010615.pub2-BIB0018|cit18","first-page":"602","article-title":"Successful stem cell mobilization rescue by AMD3100 (Plerixafor) + G-CSF for patients who failed primary mobilization: Results from the phase III (3101-NHL) study","volume":"110","author":"Micallef","year":"2007","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Micallef IN Stiff PJ DiPersio JF Maziarz RT McCarty JM Bridger G Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol Biology of Blood and Marrow Transplantation 2009 1578 86","DOI":"10.1016\/j.bbmt.2009.08.005"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Stiff PJ Micallef I Nademanee AP Stadtmauer EA Maziarz RT Bolwell BJ Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma Biology of Blood and Marrow Transplantation 2011 1146 53","DOI":"10.1016\/j.bbmt.2010.11.021"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0021|cit21","unstructured":"NCT01288573. A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy\/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01288573"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0022|cit22","unstructured":"NCT01753453. An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01753453"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0023|cit23","unstructured":"NCT01767714. Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5\u00d710^6CD34+ Cells\/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01767714?term=NCT01767714&rank=1"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0024|cit24","unstructured":"NCT02221479. Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02221479?term=NCT02221479&rank=1"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0025|cit25","unstructured":"NCT02221492. Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02221492?term=NCT02221492&rank=1"},{"issue":"4","key":"10.1002\/14651858.CD010615.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2011.133","article-title":"A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor","volume":"47","author":"Abhyankar","year":"2012","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.22038","article-title":"Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization","volume":"86","author":"Basak","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","article-title":"Improving stem cell mobilization strategies: future directions","volume":"43","author":"Bensinger","year":"2009","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD010615.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20041385","article-title":"Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist","volume":"201","author":"Broxmeyer","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010615.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0031|cit31","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Deeks","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD010615.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jca.20278","article-title":"Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield","volume":"26","author":"Duong","year":"2011","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2141.2010.08313.x","article-title":"Current status of stem cell mobilization","volume":"150","author":"Gertz","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD010615.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcome: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0035|cit35","unstructured":"International Agency for Research on Cancer Globocan 2008 http:\/\/globocan.iarc.fr"},{"issue":"2","key":"10.1002\/14651858.CD010615.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi","year":"2013","journal-title":"Critical reviews in oncology\/hematology"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0037|cit37","unstructured":"McMaster University GRADEpro 2014"},{"issue":"2-3","key":"10.1002\/14651858.CD010615.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0014-5793(03)00609-4","article-title":"Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry","volume":"546","author":"Hatse","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0039|cit39","volume-title":"Innere Medizin","author":"Herold","year":"2013"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0040|cit40","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0041|cit41","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0042|cit42","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0043|cit43","volume-title":"Plerixafor (Mozobil \u00ae) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma, DSD: Horizon Scanning in Oncology","volume":"8","author":"Hintringer","year":"2010"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bmt.2010.249","article-title":"Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program","volume":"46","author":"Hubel","year":"2011","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Jaffe ES The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research Hematology Am Soc Hematol Educ Program 2009 523 31","DOI":"10.1182\/asheducation-2009.1.523"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1600-0609.2010.01520.x","article-title":"Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies","volume":"85","author":"Jantunen","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD010615.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbmt.2011.09.009","article-title":"The evolving role of stem cell transplants in lymphomas","volume":"18","author":"Jantunen","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD010615.pub2-BIB0048|cit48","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD010615.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0050|cit50","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Lefebvre","year":"2011"},{"issue":"2","key":"10.1002\/14651858.CD010615.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2011.10.003","article-title":"Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide","volume":"18","author":"Malard","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD010615.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD010615.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004626.pub3","article-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","author":"Naumann-Winter","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD010615.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010615.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","volume":"127","author":"Phekoo","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD010615.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory\/relapsed Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0057|cit57","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"19","key":"10.1002\/14651858.CD010615.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010615.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007678.pub2","article-title":"High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults","author":"Schaaf","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010615.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD010615.pub2-BIB0061|cit61","first-page":"11","article-title":"Cancer statistics","volume":"63","author":"Siegel","year":"2012","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"11","key":"10.1002\/14651858.CD010615.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0063|cit63","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Sterne","year":"2011"},{"key":"10.1002\/14651858.CD010615.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD010615.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010615","article-title":"Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patients","author":"Hartmann","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010615.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:02:42Z","timestamp":1663059762000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010615.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010615.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}